Contact
Please use this form to send email to PR contact of this press release:
Bond Biosciences Announces Successful Pre-IND Meeting with the FDA to Advance the Development of BBI-001 for Treatment of Iron Overload Associated with Hereditary Hemochromatosis
TO: